Biagio Ricciuti receives a 2024 IASLC YIA to develop new therapies for KRAS amplified NSCLC

Biagio Ricciuti shared a post by Dana-Farber News, on X:

“Thrilled to receive a 2024 IASLC YIA to develop new therapies for KRAS amplified NSCLC. Grateful for the support and excited to work towards better treatments for our patients. With AmbrogioLab, Mark Awad and many wonderful collaborators!”

Quoting Dana-Farber News’ s post:

“Congratulations to Biagio Ricciuti, who is a recipient of the IASLC 2024 Young Investigator Grant for his work: Targeting KRAS amplification.“.

Read further.
Source: Biagio Ricciuti/X and  Dana-Farber News/X

Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.